Edgewise reports Q2 2023 net loss $21.5M; positive ARCH 12-month data for EDG-5506

Edgewise Therapeutics, Inc.

2023-Q2 EPS reported -$0.70

Cash, equivalents and marketable securities $310M as of June 30, 2023.
R&D expenses $19.6M, G&A $5.8M; net loss $0.34 per share.
ARCH study: CK reduced 37% (p=0.001), fast skeletal troponin I reduced 79% (p<0.0001) at 12 months.
GRAND CANYON pivotal cohort for Becker expected to start enrollment in 2H 2023; ~120 patients.
Phase 1 trial of EDG-7500 for HCM expected to start in 2H 2023, subject to IND clearance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Edgewise Therapeutics, Inc. reported financial results for second quarter of 2023.

Period: second quarter of 2023
Result: reported results

Exact text from the filing

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe, genetic neuromuscular and cardiac disorders for which there is significant unmet medical need, today reported financial results for the second quarter of 2023 and recent business highlights.

View on SEC.gov

Browse all earnings releases →

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001157523-23-001312

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.